Results 31 to 40 of about 13,452 (195)

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211

Pharmaceuticals, 2023
To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumor is pretargeted with a modified monoclonal antibody that has an affinity for ...
Chiara Timperanza, Holger Jensen, Tom Bäck, Sture Lindegren, Emma Aneheim   +4 more
doaj   +1 more source

Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy

Proceedings of the National Academy of Sciences of the United States of America, 2020
Significance Radioimmunotherapy is predicated on harnessing the exquisite specificity of antibodies to deliver cytotoxic radiation to tumors. Yet the long circulation time of radioimmunoconjugates leads to high radiation doses to healthy tissues ...
Outi M Keinänen, Kimberly Fung, James M Brennan, Nicholas A. Zia, M. Harris, E. van Dam, C. Biggin, Amos Hedt, J. Stoner, P. Donnelly, Jason S. Lewis, Brian M. Zeglis   +11 more
semanticscholar   +1 more source

Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin′s Lymphoma

World Journal of Nuclear Medicine, 2012
A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma.
Matthew Pickford, J. Turner
doaj   +1 more source

HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

European Journal of Nuclear Medicine and Molecular Imaging, 2020
The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and ...
B. Altunay, A. Morgenroth, M. Beheshti, A. Vogg, N. Wong, H. Ting, H. Biersack, E. Stickeler, F. Mottaghy   +8 more
semanticscholar   +1 more source

Tellurium-driven maple leaf-shaped manganese nanotherapeutics reshape tumor microenvironment via chemical transition in situ to achieve highly efficient radioimmunotherapy of triple negative breast cancer

Bioactive Materials, 2023
The therapeutic efficacy of radioimmunotherapy against triple negative breast cancer (TNBC) is largely limited by the complicated tumor microenvironment (TME) and its immunosuppressive state.
Wei Huang, Sujiang Shi, Haoran Lv, Zhenyu Ju, Qinghua Liu, Tianfeng Chen   +5 more
doaj  

Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors

Frontiers in Oncology, 2021
The prognosis of advanced malignant tumors is very poor, and effective treatment is limited. Radioimmunotherapy (RIT) is a novel treatment method. However, its anti-tumor effect is relatively low in solid tumors, which is mainly due to the blood-tumor ...
Binwei Lin, Huan Du, Jinjia Fan, Dan Huang, Feng Gao, Jie Li, Yu Zhang, Gang Feng, Tangzhi Dai, Xiaobo Du   +9 more
doaj   +1 more source

Combination of bacterial-targeted delivery of gold-based AIEgen radiosensitizer for fluorescence-image-guided enhanced radio-immunotherapy against advanced cancer

Bioactive Materials, 2023
Aggregation-Induced Emission luminogen (AIEgen) possess great potential in enhancing bioimaging-guided radiotherapeutic effects and radioimmunotherapy to improve the therapeutic effects of the tumor with good biosafety. Bacteria as a natural carrier have
Yanhong Duo, Zide Chen, Zihuang Li, Xing Li, Yaoqiang Yao, Tianzhao Xu, Ge Gao, Guanghong Luo   +7 more
doaj  

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

Molecules, 2016
The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression.
Jie Xiao, Xiaobo Xu, Xiao Li, Yanli Li, Guobing Liu, Hui Tan, Hua Shen, Hongcheng Shi, Dengfeng Cheng   +8 more
doaj   +1 more source

Current concepts of radioimmonotherapy for lymphoma [PDF]

Vojnosanitetski Pregled, 2015
nema
Mihailović Jasna, Ubavić Milan, Trifunović Jasna   +2 more
doaj   +1 more source

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

International Journal of Molecular Sciences, 2020
The use of theragnostic radiopharmaceuticals in nuclear medicine has grown rapidly over the years to combine the diagnosis and therapy of tumors. In this review, we performed web-based and desktop literature research to investigate and explain the ...
A. Cimini, M. Ricci, A. Chiaravalloti, L. Filippi, O. Schillaci   +4 more
semanticscholar   +1 more source